Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached a pivotal milestone in the development of a therapy for multiple sclerosis (MS), a disease affecting more than 2.8 million people worldwide and approximately 1 million in the USA. The company announced the completion of phase 1 clinical studies involving healthy volunteers for its patented therapeutic candidate, Lucid-MS, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Lucid-MS, marking a significant step toward clinical testing in MS patients.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and control of a person’s body. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity.
The completion of phase 1 studies and the IND submission represent a significant advancement for a therapy that targets demyelination and provides neuroprotection. The company’s focus on myelin repair addresses a critical gap in MS treatment, as many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. The favorable safety profile from the phase 1 study is a promising indicator for the potential of Lucid-MS to move into later-stage trials.
Quantum BioPharma’s progress comes at a time when the MS community is seeking therapies that can halt or reverse disability progression. The company’s newsroom at https://ibn.fm/QNTM provides updates on the program. As with all forward-looking statements, the company cautions that actual results may differ materially due to risks and uncertainties outlined in its SEC filings, including the Risk Factors sections of its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. More information on terms of use and disclaimers is available at http://IBN.fm/Disclaimer.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Advances MS Therapy with Phase 1 Completion and FDA Submission.